Nilotinib Can Be Discontinued in Some Patients with Chronic Myelogenous Leukemia

On December 22, FDA approved an update to the label of nilotinib (Tasignia) that states that some patients with CML who are taking nilotinib and whose cancer has been in remission for an extended period can safely stop taking it.

http://ift.tt/2EWRCKA